PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cell Metab. Author manuscript; available in PMC 2016 July 7.
Published in final edited form as:
PMCID: PMC4497937
NIHMSID: NIHMS689407

SLC39A14 Is Required for the Development of Hepatocellular Iron Overload in Murine Models of Hereditary Hemochromatosis

SUMMARY

Nearly all forms of hereditary hemochromatosis are characterized by pathological iron accumulation in the liver, pancreas, and heart. These tissues preferentially load iron because they take up non-transferrin-bound iron (NTBI), which appears in the plasma during iron overload. Yet, how tissues take up NTBI is largely unknown. We report that ablation of Slc39a14, the gene coding for solute carrier SLC39A14 (also called ZIP14), in mice markedly reduced the uptake of plasma NTBI by the liver and pancreas. To test the role of SLC39A14 in tissue iron loading, we crossed Slc39a14−/− mice with Hfe−/− and Hfe2−/− mice, animal models of type 1 and type 2 (juvenile) hemochromatosis respectively. Slc39a14 deficiency in hemochromatotic mice greatly diminished iron loading of the liver and prevented iron deposition in hepatocytes and pancreatic acinar cells. The data suggest that inhibition of SLC39A14 may mitigate hepatic and pancreatic iron loading and associated pathologies in iron overload disorders.

Graphical abstract

An external file that holds a picture, illustration, etc.
Object name is nihms689407u1.jpg

INTRODUCTION

Hereditary hemochromatosis is an autosomal recessive disorder that results from increased intestinal iron absorption and subsequent iron accumulation in body tissues. More than 80% of cases of hereditary hemochromatosis arise from a C282Y mutation in the HFE gene (Feder et al., 1996). With a carrier frequency of 1:200 to 1:300, the C282Y mutation is one of the most prevalent polymorphisms in individuals of northern European descent (Merryweather-Clarke et al., 1997). In HFE-related (type 1) hemochromatosis (OMIM 235200), iron absorption is increased because of inadequate synthesis of hepcidin (Bridle et al., 2003), the iron-regulatory hormone that limits iron absorption when body iron stores increase (Ganz and Nemeth, 2011). Accordingly, mutations in other genes required for hepcidin synthesis also lead to hereditary hemochromatosis. These genes include: HFE2, commonly known as hemojuvelin (Papanikolaou et al., 2004); HAMP, the hepcidin gene (Roetto et al., 2003); and TFR2, transferrin receptor 2 (Camaschella et al., 2000). Mutations in HFE2 and HAMP result in early-onset and severe iron overload, clinically referred to as juvenile (type 2) hemochromatosis (OMIM 602390). In hemochromatosis, iron loads primarily in the liver starting with periportal hepatocytes (Pietrangelo, 2010). As the disease progresses, iron accumulates in the remainder of the liver and also in the pancreas, where it deposits predominantly in acinar cells (Rahier et al., 1987). Later in the disease, iron loads in the myocardium of the heart (Carpenter et al., 2013). Clinical manifestations of hereditary hemochromatosis include hepatic fibrosis, cirrhosis, diabetes, and cardiomyopathy (Pietrangelo, 2010).

Hepcidin deficiency results not only in increased iron absorption, but also increased iron release from reticuloendothelial macrophages of the liver, spleen, and bone marrow that recycle iron from senescent red blood cells (Knutson and Wessling-Resnick, 2003). Such unregulated iron entry into the plasma leads to increased saturation of transferrin, the plasma protein that transports iron. High plasma transferrin saturations, typically >75% in hereditary hemochromatosis, are associated with the presence of a redox-active, chelatable pool of iron known as “non-transferrin-bound iron” (NTBI) (Le Lan et al., 2005). First described in thalassemia major patients in 1978 (Hershko et al., 1978), NTBI is now widely believed to be a major contributor to tissue iron loading and related pathologies in iron overload disorders (Brissot et al., 2012; Cabantchik, 2014; Fleming et al., 2005). Studies in mice have demonstrated that NTBI in the plasma is rapidly and efficiently taken up mostly by the liver and, to a lesser extent, the pancreas, kidney, and heart (Bradbury et al., 1994; Craven et al., 1987; Wang and Knutson, 2013).

Despite the importance of NTBI in the pathophysiology of iron overload, the molecular mechanisms responsible for its tissue uptake have remained elusive (Brissot et al., 2012). The most frequently proposed candidate for mediating NTBI uptake has been divalent metal-ion transporter-1, DMT1 (SLC11A2), which is required for intestinal uptake of dietary iron and iron uptake by developing erythroid cells (Gunshin et al., 2005). We recently tested the hypothesis that DMT1 plays a role in hepatic NTBI uptake by using liver-specific Dmt1 knockout mice and found that it is dispensable for hepatic NTBI uptake and hepatocyte iron loading (Wang and Knutson, 2013). A more recent candidate for NTBI uptake is SLC39A14, a member of the ZIP family of metal-ion transporters, which have mainly been characterized by their ability to transport zinc (Taylor et al., 2005). In 2006, we discovered that SLC39A14 could transport iron in addition to zinc, and that it mediated NTBI uptake by cultured AML12 mouse hepatocytes (Liuzzi et al., 2006). Subsequently, we demonstrated that SLC39A14 also mediated NTBI uptake in human hepatoma cells (Gao et al., 2008) and that the iron transport properties of SLC39A14, when expressed in Xenopus laevis oocytes, were consistent with studies of hepatic NTBI uptake in vivo (Pinilla-Tenas et al., 2011). Among human tissues, SLC39A14 is most abundantly expressed in liver, pancreas, and heart (Nomura et al., 1994; Taylor et al., 2005; Wang et al., 2012), suggesting that it may contribute to NTBI uptake and iron accumulation by these tissues in iron overload disorders. Consistent with a possible role for SLC39A14 in NTBI uptake by the liver and pancreas is our observation that SLC39A14 protein levels are elevated in iron-loaded liver and pancreas (Nam et al., 2013). Here we formally tested the role of SLC39A14 in tissue NTBI uptake and iron loading by using Slc39a14−/− mice (Hojyo et al., 2011), novel double-knockout Hfe−/−;Slc39a14−/− and Hfe2−/−;Slc39a14−/− mouse models of hereditary hemochromatosis, and Slc39a14−/− mice subjected to dietary iron overload. We show that SLC39A14 is the main NTBI transporter in the liver and pancreas, that it is essential for the development of hepatic iron overload in hemochromatosis, and that it is required for iron loading of hepatocytes and pancreatic acinar cells.

RESULTS

Ablation of Slc39a14 Impairs NTBI Uptake

To test the hypothesis that SLC39A14 plays a role in NTBI uptake in vivo, we used Slc39a14−/− mice and wild-type (WT) mice at 6 wk of age. Mice were given an intravenous injection of ferric citrate to transiently saturate plasma transferrin, followed by an intravenous injection of 59Fe-labeled ferric citrate representing NTBI. Two hours later, mice were sacrificed and tissues were harvested for gamma counting. We found that 59Fe-NTBI uptake was 70% lower in the liver and pancreas of Slc39a14−/− mice compared with WT mice (Figure 1A). By contrast, 59Fe-NTBI uptake by the kidney, spleen, and carcass was higher in Slc39a14−/− mice compared with WT controls. Analysis of hepatic 59Fe-NTBI uptake from heterozygous animals, which expressed ~50% of WT SLC39A14 protein levels (Figure 1B), indicates that one allele of Slc39a14 is sufficient for normal hepatic NTBI clearance (Figure 1C). Immunoblot analyses confirmed the lack of SLC39A14 protein in Slc39a14−/− mouse liver (Figure 1B), pancreas, heart (Nam et al., 2013) and kidney (data not shown). To investigate whether the impaired hepatic NTBI uptake in Slc39a14−/− mice is due to a defect in uptake by hepatocytes, where SLC39A14 protein is most abundantly expressed in the liver (Nam et al., 2013), we measured 59Fe-NTBI uptake in isolated primary hepatocytes. Similar to the liver, hepatocyte NTBI uptake from Slc39a14−/− mice was markedly impaired (Figure 1D).

Figure 1
Hepatic and Pancreatic Uptake of Intravenously Administered 59Fe-NTBI is Impaired in Slc39a14−/− Mice

We previously reported that SLC39A14 promotes the assimilation of transferrin-bound iron (TBI) by cultured cells (Zhao et al., 2010). Given that plasma TBI delivers iron to nearly all cells and may contribute to iron loading of the liver (Trinder and Morgan, 1997) and perhaps other tissues, we assessed whether tissue uptake of TBI is affected in Slc39a14−/− mice. We found that 59Fe uptake from TBI was not altered in the liver, pancreas, heart, kidney, and spleen of Slc39a14−/− mice (Figure 1E), indicating that SLC39A14 is dispensable for TBI uptake in these tissues.

Loss of Slc39a14 Prevents Hepatic Iron Overload in Hemochromatosis

To determine whether SLC39A14 is required for tissue iron accumulation in iron overload, we crossed Slc39a14−/− mice with Hfe−/− mice, the animal model of HFE-related hereditary hemochromatosis, to generate double-knockout Hfe−/−;Slc39a14−/− mice. Similar to patients with the C282Y mutation in HFE, Hfe−/− mice hyperabsorb dietary iron and deposit it primarily in the liver (Zhou et al., 1998). Accordingly, we found that Hfe−/− mice at 4 wk of age displayed elevated concentrations of non-heme iron, an indicator of iron stores, in the liver, but not the pancreas, heart, kidney, or spleen (Figure 2A). By contrast, Hfe−/−;Slc39a14−/− mice did not accumulate iron in the liver, but did load iron in the kidney. The lack of hepatic iron accumulation in Hfe−/−;Slc39a14−/− mice was associated not with impaired dietary iron absorption (Figure 2B) but instead with impaired hepatic iron accumulation of absorbed iron (Figure 2C). Although iron absorption did not differ significantly among groups (Figure 2B), 2-way ANOVA revealed a significant main effect of genotype, with mice lacking Hfe having significantly higher iron absorption (p < 0.05). Histochemical staining for ferric iron deposits (Perls’ stain) in liver sections from Hfe−/− mice revealed a periportal distribution of iron (Figure 2D), consistent with previous studies (Fleming et al., 2001; Zhou et al., 1998). In Hfe−/−;Slc39a14−/− mice, negligible amounts of iron were detectable by using Perls’ stain (Figure 2E) or the more sensitive DAB-enhanced Perls’ stain (Figure 2F). Given that the liver can take up iron from the plasma, we measured plasma iron concentrations, total iron-binding capacity (TIBC), transferrin saturation, and plasma concentrations of NTBI (Figure 2G–J). Plasma iron indices were not significantly affected by loss of Slc39a14, indicating that the lack of hepatic iron accumulation in Hfe−/−;Slc39a14−/− mice is not due to diminished levels of plasma iron. As in our previous study (Hojyo et al., 2011), body weights of 4-wk-old Slc39a14−/− mice were lower than those of WT mice (Figure 2K). Body weights of Hfe−/−;Slc39a14−/− mice tended to be lower than WT or Hfe−/− mice, but the difference was not statistically significant. Tissue non-heme iron concentrations were also assessed at 16 wk of age (Figure S1D). Similar to 4-wk-old mice, 16-wk-old Hfe−/− ;Slc39a14−/− mice displayed a marked impairment in hepatic iron accumulation and enhanced iron accumulation in the kidney. In addition, non-heme iron concentrations in the pancreas and heart were 60% and 24% higher, respectively, in Hfe−/−;Slc39a14−/− mice compared to Slc39a14−/− animals.

Figure 2
Ablation of Slc39a14 in Hfe−/− Mice Impairs Hepatic Iron Loading

To determine what effect a loss of Slc39a14 would have in a more severe form of hemochromatosis, we generated double-knockout Hfe2−/−;Slc39a14−/− mice. Hfe2−/− mice, the animal model for juvenile hemochromatosis, develop rapid and massive iron overload, with iron depositing primarily in the liver and secondarily in the pancreas and heart (Niederkofler et al., 2005). Hfe2−/− mice at 6 wk of age exhibited elevated iron content of the liver (~ 15 fold), pancreas (~ 17 fold), and heart (~ 1 fold) compared with WT controls (Figure 3A). Similar to Hfe−/−;Slc39a14−/− mice, double-knockout Hfe2−/−;Slc39a14−/− mice displayed a marked impairment in iron loading of the liver (Figure 3A). In addition, iron loading of the pancreas was 60% less in Hfe2−/−;Slc39a14−/− mice compared with Hfe2−/− controls. Interestingly, in comparison with Hfe2−/− animals, Hfe2−/−;Slc39a14−/− mice displayed 26% higher non-heme iron concentrations in the heart and markedly elevated iron concentrations in the kidney and spleen (2.6 and 11 fold respectively). These observations demonstrate that the heart, kidney, and spleen have SLC39A14-independent pathways of iron accumulation.

Figure 3
Ablation of Slc39a14 in the Hfe2−/− Mouse Model of Juvenile Hemochromatosis Prevents Hepatic Iron Overload

As expected, iron absorption was markedly elevated in Hfe2−/− mice (Figure 3B). Iron absorption was also elevated in Hfe2−/−;Slc39a14−/− mice compared to WT or Slc39a14−/− animals but was 25% lower than in Hfe2−/− mice. The lower iron absorption in Hfe2−/−;Slc39a14−/− mice was not associated with differences in enterocyte protein levels of DMT1, the apical iron importer, or ferroportin (FPN), the basolateral iron exporter (Figure S2). Similar to Hfe−/−;Slc39a14−/− mice (Figure 2C), Hfe2−/−;Slc39a14−/− mice showed diminished hepatic accumulation of absorbed iron compared with Hfe2−/− animals (Figure 3C). A trend of enhanced uptake of absorbed iron into the pancreas of Hfe2−/−;Slc39a14−/− mice was observed, but it did not reach statistical significance with this limited sample size (n = 4) (Figure 3D). Consistent with previous findings (Niederkofler et al., 2005), Hfe2−/− mice displayed reduced concentrations of iron in the spleen (Figure 3A), likely due to increased iron release by reticuloendothelial macrophages of the red pulp. Consequently, splenic accumulation of absorbed iron was markedly lower in Hfe2−/− mice compared to WT controls (Figure 3E). By contrast, splenic accumulation of absorbed iron was not lower in Hfe2−/−;Slc39a14−/− mice (Figure 3E). Perls’ stain of liver sections revealed massive iron deposition throughout hepatocytes of Hfe2−/− mice, but no iron deposits were detected in hepatocytes of Hfe2−/−;Slc39a14−/− mice (Figure 3F, G). By using DAB-enhanced Perls’ stain, however, iron deposits became detectable in non-parenchymal cells of the livers of Hfe2−/−;Slc39a14−/− mice (Figure 3H). Co-staining with the macrophage marker F4/80 and Perl’s stain indicates that some, but not all, of the iron was present in Kupffer cells (Figure S3A). Loss of Slc39a14 in the single- or double-knockout mice did not affect TIBC, transferrin saturation, or plasma NTBI concentrations (Figure 3J–L). Mice lacking Hfe2 had higher plasma NTBI concentrations relative to their respective controls (Figure 3L). Body weights were lower in Hfe2−/−;Slc39a14−/− mice than in Hfe2−/− and Slc39a14−/− controls (Figure 3M). Older Hfe2−/−; Slc39a14−/− mice (12 wk of age) displayed alterations in tissue non-heme iron concentrations that were similar to those observed at 6 wk of age (Figure S1E).

Loss of Slc39a14 Alters Pancreatic Iron Accumulation

Given that the pancreas accumulates iron from NTBI (Craven et al., 1987) and that Slc39a14−/− mice showed impaired pancreatic NTBI uptake (Figure 1A), we expected that Slc39a14−/− mice would display impaired iron loading of this organ. Although we did find that pancreatic iron loading was impaired in Hfe2−/−;Slc39a14−/− mice relative to Hfe2−/− mice, iron still accumulated to levels that were roughly 10 times normal (Figure 3A). In an effort to identify which cell types of the pancreas accumulated iron, we used DAB-enhanced Perls’ stain, which was needed because Perls’ stain was not sensitive enough to detect the low amounts of iron in this tissue at this age. Serial pancreas sections were counterstained with neutral red (+NR) to visualize tissue structures or processed without neutral red (−NR) to better see the iron deposits. Similar to a previous report (Niederkofler et al., 2005), Hfe2−/− mice accumulated iron predominantly in pancreatic acinar cells, with little iron detectable in islets (Figure 4A). However, in Hfe2−/−;Slc39a14−/− mice, iron was not detected in acinar cells; instead, strong staining was observed in inter- and perilobular regions (Figure 4A). To identify which pancreatic structures were loading iron, we analyzed serial tissue sections by using immunohistochemistry and the protein markers PCK-26 for ductal epithelium, CD-31 for blood vessel endothelium, LYVE-1 for lymphatic endothelium, and collagen I for connective tissue. The iron staining overlapped best with collagen I (Figure 4B), suggesting that iron is depositing in connective tissue in the pancreas of Hfe2−/−;Slc39a14−/− mice. Iron loading in pancreatic connective tissue has been reported previously (Giorgi and Roque, 2014). The altered pattern of pancreatic iron deposition in Hfe2−/−;Slc39a14−/− mice is readily observed by Perls’ staining of pancreas sections from 12-wk-old mice (Figure S4A).

Figure 4
Hfe2−/−;Slc39a14−/− Mice Display Altered Iron Loading in the Pancreas

Loss of Slc39a14 in Dietary Iron Overload

The data from the Hfe−/−;Slc39a14−/− and Hfe2−/−;Slc39a14−/− mice show that Slc39a14 is required for the development of hepatic iron overload in mouse models of hemochromatosis. Given that the loss of Hfe and Hfe2 results in hemochromatosis by impairing hepcidin expression, we next sought to examine what effect the loss of Slc39a14 alone would have in the development of iron overload in mice having intact hepcidin regulation. To induce iron overload, WT and Slc39a14−/− mice were fed an iron-overloaded (FeO) diet for 4 wk. Similar to the Hfe−/−;Slc39a14−/− and Hfe2−/−;Slc39a14−/− mice, Slc39a14−/− mice fed the FeO diet (Slc39a14−/−-FeO mice) displayed a marked impairment in iron accumulation in the liver and increased iron loading in the pancreas, heart, kidney, and spleen (Figure 5A). Yet unlike in the genetic models of iron overload, Slc39a14−/−-FeO mice did accumulate a moderate amount of iron in the liver. However, Perls’ stain of liver tissue sections from Slc39a14−/−-FeO mice revealed a markedly altered cellular distribution of iron. In WT-FeO mice, iron predominantly accumulated in periportal hepatocytes (Figure 5B–C), whereas in Slc39a14−/−-FeO mice, iron was found throughout the liver in non-parenchymal cells (Figure 5B–C), including Kupffer cells (Figure S3B). Magnification of a portal region from Slc39a14−/− mice revealed no detectable iron in hepatocytes (Figure 5C), even by using the highly sensitive DAB-enhanced Perls’ stain (Figure 5D). DAB-enhanced Perls’ stain of pancreas sections from Slc39a14−/−-FeO mice revealed a pattern of iron deposition similar to that seen in Hfe2−/−;Slc39a14−/− mice, i.e., iron staining in inter- and perilobular regions (Figure S4B). Plasma iron and NTBI concentrations did not differ among groups (Figure 5E, H), but transferrin saturations were higher in Slc39a14−/−-FeO mice (Figure 5G), mainly because of lower TIBC (Figure 5F). Body weights of Slc39a14−/−-FeO mice were lower than those of WT-FeO mice or Slc39a14−/−-FeC mice (Figure 5I).

Figure 5
Slc39a14−/− Mice Display Altered Hepatic Iron Loading in Response to Dietary Iron Overload

Loss of Slc39a14 and Hepcidin Expression

Because the loss of Slc39a14 impairs/alters hepatic iron accumulation in the three models of iron overload used in this study, we next asked whether these alterations would have an effect on hepatic expression of hepcidin, the iron-regulatory hormone produced mainly by the liver. We also measured hepatic mRNA levels of BMP6, a key endogenous regulator of hepcidin expression that is induced by hepatic iron loading (Kautz et al., 2008). Collectively, no differences in hepcidin mRNA levels were observed in Slc39a14−/− mice compared to their respective controls (Figure 6A–C). Interestingly however, BMP6 levels were elevated in iron-loaded Slc39a14−/− mice across all models used in the current study (Figure 6A–C), despite these animals having markedly lower hepatic iron concentrations compared to their respective controls. For example, Hfe2−/− and Hfe2−/−;Slc39a14−/− mice had similarly elevated BMP6 mRNA levels (i.e., 2.5-fold higher than WT or Slc39a14−/− mice) (Figure 6B), yet Hfe2−/−;Slc39a14−/− mice had hepatic iron concentrations that were 12-fold lower than those in Hfe2−/− mice (i.e., 99 vs. 1292 mg Fe/g liver, Figure 3A). In Slc39a14−/−-FeO mice, BMP6 mRNA levels were higher than those in WT-FeO mice (Figure 6C) despite these animals having 70% less iron in the liver (Figure 5A).

Figure 6
Hepatic Expression of Hamp and Bmp6 mRNA in Slc39a14−/− Mice with Genetic or Dietary Iron Overload

Although BMP6 is known to upregulate hepcidin expression, higher levels of BMP6 mRNA in Slc39a14−/−-FeO mice compared with WT-FeO mice were not associated with further increases in hepcidin expression (Figure 6C). We initially thought that this result could be confounded by anemia, which we unexpectedly documented in a repeat study that we performed to obtain hemoglobin levels in the Slc39a14−/−-FeO mice (Figure S5F). Anemia and associated stress erythropoiesis are known to cause the release of erythroid factors such as erythroferrone that suppress hepcidin expression (Kautz et al., 2012). However, in a 3-day iron overload feeding study, which did not affect hemoglobin levels in the Slc39a14−/− mice, we again found elevated levels of BMP6 mRNA that were not associated with further increases in hepcidin expression (Figure S6) Our observations are similar to a dietary iron overload study in mice showing that increased BMP6 mRNA levels higher than 2-fold baseline are not associated with further increases in hepcidin mRNA (Corradini et al., 2011). Collectively, these observations suggest that BMP6 regulation of hepcidin expression becomes saturated at relatively low BMP6 expression levels. Nevertheless, additional studies are needed to determine if the unexpected hepcidin response in anemic Slc39a14−/−-FeO mice is associated with erythropoiesis-driven factors that repress hepatic hepcidin production.

Loss of Slc39a14 Alters Splenic Iron Accumulation

The accumulation of iron in the spleen in Hfe2−/−;Slc39a14−/− mice (Figure 3A) was unexpected as these animals also expressed very low levels of hepcidin similar to Hfe2−/− mice (Figure 6B). Low hepcidin expression in Hfe2−/− mice is normally associated with decreased splenic iron concentrations as observed in the present study (Figure 3A) and by others (Huang et al., 2005; Niederkofler et al., 2005). The lower splenic iron concentrations in Hfe2−/− mice are thought to arise from impaired hepcidin expression, which in turn, fails to down-regulate FPN expression in red pulp macrophages involved in recycling iron from senescent red blood cells. The elevated FPN levels and the resulting enhanced iron export in splenic macrophages therefore causes splenic iron levels to decrease. Our observation of splenic iron loading along with low hepcidin expression in Hfe2−/−;Slc39a14−/− mice prompted us to examine the pattern of iron deposition and FPN expression in the spleen. Perls’ staining of spleen sections from Hfe2−/−;Slc39a14−/− mice revealed that iron accumulated in F4/80-positive macrophages of the red pulp (Figure S5A), with iron loading in cells expressing FPN (Figure S5B). One possible explanation for this observation is that when iron uptake by the liver and pancreas are impaired in iron-loaded Hfe2−/−;Slc39a14−/− mice, NTBI in plasma is taken up by SLC39A14-independent mechanisms in splenic macrophages at a rate that exceeds the capacity of FPN to export the accumulated iron. Given that plasma NTBI concentrations did not differ between Hfe2−/− and Hfe2−/−;Slc39a14−/− mice, it is also possible that the chemical composition of NTBI in Hfe2−/−;Slc39a14−/− mice is different, favoring macrophage uptake. Selective uptake of different chemical forms of NTBI has been postulated to contribute to the different tissue iron loading patterns observed in various iron overload disorders (Arezes et al., 2013). More likely, however, the iron accumulation in red pulp macrophages of Hfe2−/−;Slc39a14−/− mice is probably related to hemolysis, as suggested by lower hemoglobin levels, fewer total RBCs, normal MCV, and increased reticulocyte counts (Figure S5E and Table S1). Indeed, hemolysis may also be contributing to the anemia (Figure 5SF, Table S2) and pronounced splenic iron accumulation in Slc39a14−/− mice subjected to dietary iron overload (Figure 5A, Figure S5C).

DISCUSSION

In diseases of iron overload, the liver is the primary organ that accumulates iron, resulting in increased risk for hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (Pietrangelo, 2010). Yet, how the liver loads iron is largely unknown (Andrews, 2008; Wang and Knutson, 2013). Our present studies using double knockout Hfe−/−;Slc39a14−/− and Hfe2−/−;Slc39a14−/− mice reveal that Slc39a14 is required for the development of hepatic iron overload in hereditary hemochromatosis. This is observed for both male and female mice, which are known to vary in iron status (Figure S1A, B). Furthermore, the observation that Slc39a14−/− mice displayed a marked impairment in the uptake of NTBI but not of TBI supports the hypothesis that NTBI is the main contributor to hepatic iron loading in iron overload disorders (Brissot et al., 2012).

Consistent with the double knockout mice, Slc39a14−/− mice subjected to dietary iron overload did not accumulate iron in hepatocytes; however, they did accumulate iron in hepatic macrophages (Kupffer cells), likely because these animals up-regulated the expression of hepcidin, which blocks macrophage iron release (Knutson et al., 2005). Collectively, our genetic and dietary models of iron overload indicate that SLC39A14 is required for hepatocyte iron loading. Our data from Hfe2−/−;Slc39a14−/− mice and dietary iron-loaded Slc39a14−/− mice further suggest that SLC39A14 is required for iron loading of pancreatic acinar cells, the cell type of the pancreas that preferentially loads iron in hereditary hemochromatosis (Lesbordes-Brion et al., 2006; Nick et al., 2009).

Although SLC39A14 appears to be the main pathway for NTBI uptake by the liver and pancreas, our data indicate that SLC39A14 is dispensable for NTBI uptake and iron loading of the heart. Cardiac iron accumulation can lead to iron-overload cardiomyopathy, estimated to account for one third of deaths in hemochromatosis patients (Kremastinos and Farmakis, 2011). Our NTBI injection experiments indicate that the heart normally takes up very little plasma NTBI—in fact about 100 times less than the liver and 10 times less than the pancreas. These relative differences in NTBI uptake likely account for the observation that cardiac iron loading is usually a late manifestation of iron overload, occurring after the liver and pancreas become loaded with iron (Noetzli et al., 2009; Subramaniam et al., 2012). The finding that SLC39A14 is dispensable for cardiac NTBI uptake may be because SLC39A14 protein levels are markedly lower in the heart than in the pancreas or liver (Nam et al., 2013). Possible alternative NTBI transporters in the heart include L-type Ca2+ channels (Oudit et al., 2006), T-type Ca2+ channels (Kumfu et al., 2011), or SLC39A8, which is closely related to SLC39A14 (Wang et al., 2012).

Based on the data presented here, we propose the following model for NTBI uptake and tissue iron loading in hereditary hemochromatosis. In hemochromatosis, hepcidin levels are abnormally low, resulting in increased iron release from reticuloendothelial macrophages and increased intestinal iron absorption. The increased iron release into the circulation causes transferrin saturations to be high or fully saturated; therefore, most of the iron absorbed by the intestine or released from splenic macrophages will enter the portal circulation as NTBI. The liver efficiently takes up NTBI from portal blood via SLC39A14 located on the sinusoidal membrane of hepatocytes (Nam et al., 2013) (Figure 6D). SLC39A14-mediated NTBI uptake by hepatocytes largely explains why the liver is the first and foremost organ that accumulates iron in hereditary hemochromatosis. NTBI not taken up by the liver is subsequently taken up mostly by SLC39A14 expressed by pancreatic acinar cells (Figure 6D), and to a lesser extent by SLC39A14-independent NTBI transporters in the heart and other tissues. In hemochromatotic mice lacking SLC39A14, NTBI in portal blood bypasses the liver and is taken up mainly by the kidney, after being filtered through the glomeruli and reabsorbed in the proximal tubule by luminal transporters such as DMT1 or SLC39A8 (Canonne-Hergaux and Gros, 2002; Fujishiro et al., 2012).

The observation that hepatic hepcidin mRNA expression was unaffected by the loss of Slc39a14, either in single- or double-knockout mice, indicates that the markedly altered tissue distribution of iron in Slc39a14−/− mice does not arise because of altered expression of hepcidin, the master hormone that controls whole-body iron balance (Ganz and Nemeth, 2011). Our data additionally show that hepatic hepcidin mRNA, produced predominantly by hepatocytes, can be induced in the absence of detectable hepatocyte iron loading. In mice, hepcidin expression requires BMP6, a cytokine that triggers the BMP6/SMAD4-signaling pathway, ultimately activating hepcidin transcription (Andriopoulos et al., 2009; Meynard et al., 2009). Iron loading of the liver induces the expression of BMP6 (Kautz et al., 2008), which increases the expression of hepcidin. Although the hepatic cell type that increases BMP6 expression in response to iron loading remains unresolved, studies of isolated liver cells suggest that non-parenchymal cells (Kupffer cells, stellate cells, and sinusoidal endothelial cells) are the main source (Enns et al., 2013; Feng et al., 2012). Our data support this view in that up-regulated BMP6 mRNA levels in iron-loaded Slc39a14−/− mice were associated with iron loading in non-parenchymal cells but not hepatocytes (Figure 6D).

In contrast to the dramatic alterations in iron metabolism observed in Slc39a14−/− mice with iron overload, only minor perturbations in iron metabolism were observed in normal Slc39a14−/− mice (i.e., single-mutant Slc39a14−/− mice consuming diets with normal amounts of iron). One consistent finding was that liver non-heme iron concentrations were ~35% lower in young Slc39a14−/− mice compared with WT animals. This difference was observed at 4, 6, and 7 wk of age (Figure 2A, Figure 3A, Figure 5A, respectively). By 12–16 wk, however, liver non-heme iron concentrations did not differ between groups (Figure S1D, E). We originally reported that liver iron levels were unaffected in normal Slc39a14−/− mice (Hojyo et al., 2011), but these data were from pool of mice of various ages (4, 8 and 16 wk) as we later noted (Nam et al., 2013). A recent study reported that Slc39a14−/− mice had liver non-heme iron concentrations that were ~50% higher than WT mice (Beker Aydemir et al., 2012), but the age of the mice were not specified (only a range of 8–16 wk was noted), and iron metabolism was not examined in the context of iron overload.

In conclusion, we identify SLC39A14 as the major route for NTBI uptake into hepatocytes and pancreatic acinar cells in iron overload and show that SLC39A14 is essential for iron loading of the liver in hereditary hemochromatosis. Our data raise the possibility that inhibitors of SLC39A14 activity or expression could be used to prevent hepatic iron loading in iron overload diseases, including transfusion-dependent thalassemia major, for which there is no cure at the present time. Such a strategy, however, would need to be used in conjunction with iron chelators that bind and remove NTBI from the plasma to prevent it from depositing in extrahepatic tissues.

EXPERIMENTAL PROCEDURES

Animals and Diets

Slc39a14+/− mice were originally on a mixed 129+Ter/SvJcl x C57BL/6 background (Hojyo et al., 2011). For tissue NTBI and TBI uptake measurements and the feeding study, Slc39a14−/− mice and wild-type (WT) control littermates were on a mixed 129+Ter/SvJcl x C57BL/6 x Balb/cJ background. For studies with double knockout mice, Slc39a14+/− mice were intercrossed with Hfe+/− mice (Levy et al., 1999) or Hfe2+/− mice (JAX Mice) on a 129S6/SvEvTac background to generate homozygous double knockout mice along with single-mutant and WT littermate controls. Mice were genotyped at weaning by extracting genomic DNA from tail snip samples followed by PCR analysis. Mice were weaned at 3 wk of age, maintained on a standard diet (Teklad 7912, Harlan Laboratories) containing 240 ppm iron, and housed in a 12-h light-dark cycle. In the feeding study, mice were fed modified AIN-93G rodent diet formulated to contain 50 ppm iron (iron control, FeC; Harlan Laboratories, diet TD.130018) or 10,000 ppm (1%) carbonyl iron (iron overloaded, FeO; Harlan Laboratories, diet TD.130015) for 4 wk. Mice in all studies were of mixed sex unless otherwise noted. The numbers of male and female mice used in all experiments are outlined in Tables S3 and S4. Animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Florida.

Measurement of In Vivo Tissue NTBI and TBI Uptake

Tissue NTBI uptake was measured after intravenous administration of radiolabeled iron (Craven et al., 1987). Six-wk-old mice were injected via tail vein with 70 μg ferric citrate in 0.1 ml of 0.1 M citric acid buffer (pH 6.6) to transiently saturate plasma transferrin. Ten min later, 59Fe-labeled ferric-citrate (2 μCi) was administered via tail vein. Mice were sacrificed 2 h later and whole-body and tissue 59Fe-associated radioactivity (counts per min, cpm) were determined by using a WIZARD2 gamma counter (PerkinElmer). For tissue TBI uptake (Wang and Knutson, 2013), mice were injected via tail vein with 150 μg 59Fe-labelled transferrin (2 μCi). Two h later, animals were sacrificed and whole-body and tissue radioactivity were determined by gamma counting. NTBI and TBI uptakes were calculated as a percentage of whole-body cpm.

Primary Hepatocyte Isolation and Hepatocyte NTBI Uptake

Primary hepatocytes were isolated from 13-wk-old mice by collagenase perfusion as detailed in Supplemental Information. Cellular uptake of NTBI (59Fe-labeled ferric citrate) was measured as described previously (Wang et al., 2012) and as detailed in Supplemental Information.

Measurement of Iron Absorption

Iron absorption was determined by 59Fe gavage (Ajioka et al., 2002). Five-wk-old mice were fasted overnight and then gavaged with 0.2 mL 59Fe-labeled iron solution containing ~2.5 μCi 59Fe-HCl, 0.5 M ascorbic acid, 0.15 M NaCl and FeSO4 for a final total of 5 μg Fe. After gavage, mice were returned to their cages, provided with water, fasted for 7 h, and then provided with food overnight. Approximately 24 h after gavage, mice were sacrificed and dissected. The gastrointestinal (GI) tract was removed and major organs and carcass were analyzed for radioactivity by gamma counting. Percentage iron absorption was calculated as: (absorbed cpm/cpm of iron administered by gavage) × 100. Iron accumulation in various organs after 59Fe gavage was calculated as: organ cpm/ absorbed cpm × 100. Absorbed cpm refers to the radioactivity in the whole body (determined by the sum of major organs and carcass cpm) without the GI tract.

Iron Status Parameters

Plasma iron, total iron-binding capacity, transferrin saturation, and tissue non-heme iron concentrations were determined as described previously (Wang and Knutson, 2013). Plasma NTBI was measured by using a colorimetric method (Gosriwatana et al., 1999). The distribution of storage iron in deparaffinized formalin-fixed tissues sections was visualized by using Perls’ Prussian blue stain or diaminobenzidine (DAB)-enhanced Perls’ stain containing cobalt chloride, which further enhances sensitivity and produces a black reaction product providing more contrast (Adams, 1981) as detailed in Supplemental Information. Slides were counterstained with 1% neutral red solution or hematoxylin QS (Vector Labs) and visualized with an Olympus IX70 inverted microscope and QImaging QCapture Pro 6.0 Software.

Immunoblot Analyses

Immunoblot analyses and sample preparation are detailed in Supplemental Information.

Immunohistochemistry

For immunohistochemical analysis, paraffin-embedded pancreas sections (except those for LYVE-1) were processed for antigen retrieval in sodium citrate buffer (pH 6.0). Slides were incubated for 30 min with primary antibody against PCK-26 (1:500; Abcam, ab6401), CD-31 (1:50; Abcam, ab28364), LYVE-1 (1:50; Abcam; ab14917) or collagen-I (1:100; NB600-408, Novus Biologicals). After incubation with species-specific biotinylated secondary antibodies (1:200) for 30 min and streptavidin-HRP for 30 min (Vectastain, ABC kit; Vector Labs), the immunoperoxidase reaction was visualized by using the VECTOR NovaRED Peroxidase HRP Substrate Kit (Vector Labs). Slides were counterstained with hematoxylin QS and visualized with an Olympus IX70 inverted microscope and QImaging QCapture Pro 6.0 Software.

RNA extraction and Quantitative Reverse-Transcriptase PCR

Total RNA was isolated from liver samples by using RNAzol RT reagent (Molecular Research Center). First-strand cDNA synthesis was performed by using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). PCR reactions were carried out by using the Power SYBR Green PCR kit (Applied Biosystems) on the ABI 7300 Real-Time PCR system (Applied Biosystems). Gene-specific primers used for PCR are listed in Supplemental Information.

Statistical Analyses

All data are shown as the mean ± SEM. Means were compared by using, where appropriate, Student’s unpaired t-test or one-way ANOVA with Tukey’s post-hoc test. A p-value < 0.05 was considered statistically significant. Data sets with unequal variances were log-transformed prior to statistical analysis. Analyses were performed by using PRISM software (GraphPad).

HIGHLIGHTS

  • SLC39A14 mediates non-transferrin-bound iron uptake by the liver and pancreas
  • SLC39A14 is required for Hfe−/− and Hfe2−/− mice to develop hepatic iron overload
  • SLC39A14 is required for iron loading of hepatocytes and pancreatic acinar cells
  • SLC39A14 represents a possible therapeutic target for mitigating tissue iron loading

Supplementary Material

Acknowledgments

This work was supported by the National Institutes of Health grants DK080706 (to M.D.K.), DK079879 and DK090115 (J-S.K.), and the National Institute on Aging grant AG028740 (J-S K.). We thank Martha Campbell-Thompson (Department of Medicine, University of Florida) for help with anatomy and immunohistochemistry of the pancreas, and Dr. Herbert Y. Lin (Harvard Medical School, Boston, MA) for assistance with studies on Hfe2−/− mice.

Footnotes

AUTHOR CONTRIBUTIONS

M.D.K., S.J., and C.W. designed the experiments and analyzed the data. M.D.K., S.J., T.F. and S.H. wrote the manuscript. S.J., C.W., R.C., and W.Z. performed the mouse experiments, iron analyses, and immunohistochemistry. A.C. assisted with mouse breeding and genotyping. T.B. and J-S.K. isolated primary mouse hepatocytes. S.H. and T.F. provided the Slc39a14−/− mice.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Adams JC. Heavy metal intensification of DAB-based HRP reaction product. J Histochem Cytochem. 1981;29:775. [PubMed]
  • Ajioka RS, Levy JE, Andrews NC, Kushner JP. Regulation of iron absorption in Hfe mutant mice. Blood. 2002;100:1465–1469. [PubMed]
  • Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112:219–230. [PubMed]
  • Andriopoulos B, Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, Knutson MD, Pietrangelo A, Vukicevic S, Lin HY, Babitt JL. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482–487. [PMC free article] [PubMed]
  • Arezes J, Costa M, Vieira I, Dias V, Kong XL, Fernandes R, Vos M, Carlsson A, Rikers Y, Porto G, Rangel M, Hider RC, Pinto JP. Non-transferrin-bound iron (NTBI) uptake by T lymphocytes: evidence for the selective acquisition of oligomeric ferric citrate species. PLoS One. 2013;8:e79870. [PMC free article] [PubMed]
  • Beker Aydemir T, Chang SM, Guthrie GJ, Maki AB, Ryu MS, Karabiyik A, Cousins RJ. Zinc transporter ZIP14 functions in hepatic zinc, iron and glucose homeostasis during the innate immune response (endotoxemia) PLoS One. 2012;7:e48679. [PMC free article] [PubMed]
  • Bradbury MW, Raja K, Ueda F. Contrasting uptakes of 59Fe into spleen, liver, kidney and some other soft tissues in normal and hypotransferrinaemic mice. Influence of an antibody against the transferrin receptor. Biochem Pharmacol. 1994;47:969–974. [PubMed]
  • Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramaniam VN, Powell LW, Anderson GJ, Ramm GA. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361:669–673. [PubMed]
  • Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: A key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012;1820:403–410. [PubMed]
  • Cabantchik ZI. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front Pharmacol. 2014;5:45. [PMC free article] [PubMed]
  • Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, Gasparini P. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25:14–15. [PubMed]
  • Canonne-Hergaux F, Gros P. Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. Kidney Int. 2002;62:147–156. [PubMed]
  • Carpenter JP, Grasso AE, Porter JB, Shah F, Dooley J, Pennell DJ. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson. 2013;15:24. [PMC free article] [PubMed]
  • Corradini E, Meynard D, Wu Q, Chen S, Ventura P, Pietrangelo A, Babitt JL. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology. 2011;54:273–284. [PMC free article] [PubMed]
  • Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci U S A. 1987;84:3457–3461. [PubMed]
  • Enns CA, Ahmed R, Wang J, Ueno A, Worthen C, Tsukamoto H, Zhang AS. Increased iron loading induces Bmp6 expression in the non-parenchymal cells of the liver independent of the BMP-signaling pathway. PLoS One. 2013;8:e60534. [PMC free article] [PubMed]
  • Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408. [PubMed]
  • Feng Q, Migas MC, Waheed A, Britton RS, Fleming RE. Ferritin upregulates hepatic expression of bone morphogenetic protein 6 and hepcidin in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1397–1404. [PubMed]
  • Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathophysiology of hereditary hemochromatosis. Semin Liver Dis. 2005;25:411–419. [PMC free article] [PubMed]
  • Fleming RE, Holden CC, Tomatsu S, Waheed A, Brunt EM, Britton RS, Bacon BR, Roopenian DC, Sly WS. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A. 2001;98:2707–2711. [PubMed]
  • Fujishiro H, Yano Y, Takada Y, Tanihara M, Himeno S. Roles of ZIP8, ZIP14, and DMT1 in transport of cadmium and manganese in mouse kidney proximal tubule cells. Metallomics. 2012;4:700–708. [PubMed]
  • Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347–360. [PubMed]
  • Gao J, Zhao N, Knutson MD, Enns CA. The hereditary hemochromatosis protein, HFE, inhibits iron uptake via down-regulation of Zip14 in HepG2 cells. J Biol Chem. 2008;283:21462–21468. [PMC free article] [PubMed]
  • Giorgi G, Roque ME. Iron overload induces changes of pancreatic and duodenal divalent metal transporter 1 and prohepcidin expression in mice. Acta Histochem. 2014;116:354–362. [PubMed]
  • Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999;273:212–220. [PubMed]
  • Gunshin H, Fujiwara Y, Custodio AO, Direnzo C, Robine S, Andrews NC. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest. 2005;115:1258–1266. [PubMed]
  • Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40:255–263. [PubMed]
  • Hojyo S, Fukada T, Shimoda S, Ohashi W, Bin BH, Koseki H, Hirano T. The zinc transporter SLC39A14/ZIP14 controls G-protein coupled receptor-mediated signaling required for systemic growth. PLoS One. 2011;6:e18059. [PMC free article] [PubMed]
  • Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. J Clin Invest. 2005;115:2187–2191. [PMC free article] [PubMed]
  • Kautz L, Meynard D, Monnier A, Darnaud V, Bouvet R, Wang RH, Deng C, Vaulont S, Mosser J, Coppin H, Roth MP. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112:1503–1509. [PubMed]
  • Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–684. [PMC free article] [PubMed]
  • Knutson M, Wessling-Resnick M. Iron metabolism in the reticuloendothelial system. Crit Rev Biochem Mol Biol. 2003;38:61–88. [PubMed]
  • Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci U S A. 2005;102:1324–1328. [PubMed]
  • Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124:2253–2263. [PubMed]
  • Kumfu S, Chattipakorn S, Srichairatanakool S, Settakorn J, Fucharoen S, Chattipakorn N. T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur J Haematol. 2011;86:156–166. [PubMed]
  • Le Lan C, Loreal O, Cohen T, Ropert M, Glickstein H, Laine F, Pouchard M, Deugnier Y, Le Treut A, Breuer W, Cabantchik ZI, Brissot P. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood. 2005;105:4527–4531. [PubMed]
  • Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, Houbron C, Hamard G, Kahn A, Vaulont S. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood. 2006;108:1402–1405. [PubMed]
  • Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood. 1999;94:9–11. [PubMed]
  • Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci U S A. 2006;103:13612–13617. [PubMed]
  • Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34:275–278. [PMC free article] [PubMed]
  • Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41:478–481. [PubMed]
  • Nam H, Wang CY, Zhang L, Zhang W, Hojyo S, Fukada T, Knutson MD. ZIP14 and DMT1 in the liver, pancreas, and heart are differentially regulated by iron deficiency and overload: implications for tissue iron uptake in iron-related disorders. Haematologica. 2013;98:1049–1057. [PubMed]
  • Nick H, Allegrini PR, Fozard L, Junker U, Rojkjaer L, Salie R, Niederkofler V, O’Reilly T. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. Exp Biol Med (Maywood) 2009;234:492–503. [PubMed]
  • Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest. 2005;115:2180–2186. [PMC free article] [PubMed]
  • Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114:4021–4026. [PubMed]
  • Nomura N, Nagase T, Miyajima N, Sazuka T, Tanaka A, Sato S, Seki N, Kawarabayasi Y, Ishikawa K, Tabata S. Prediction of the coding sequences of unidentified human genes. II The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1994;1:223–229. [PubMed]
  • Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl) 2006;84:349–364. [PubMed]
  • Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson J, Risler JK, Zaborowska C, Babakaiff R, Radomski CC, Pape TD, Davidas O, Christakis J, Brissot P, Lockitch G, Ganz T, Hayden MR, Goldberg YP. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77–82. [PubMed]
  • Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393–408. [PubMed]
  • Pinilla-Tenas JJ, Sparkman BK, Shawki A, Illing AC, Mitchell CJ, Zhao N, Liuzzi JP, Cousins RJ, Knutson MD, Mackenzie B. Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound iron. Am J Physiol Cell Physiol. 2011;301:C862–871. [PubMed]
  • Rahier J, Loozen S, Goebbels RM, Abrahem M. The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia. 1987;30:5–12. [PubMed]
  • Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21–22. [PubMed]
  • Subramaniam VN, McDonald CJ, Ostini L, Lusby PE, Wockner LF, Ramm GA, Wallace DF. Hepatic iron deposition does not predict extrahepatic iron loading in mouse models of hereditary hemochromatosis. Am J Pathol. 2012;181:1173–1179. [PubMed]
  • Taylor KM, Morgan HE, Johnson A, Nicholson RI. Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett. 2005;579:427–432. [PubMed]
  • Trinder D, Morgan E. Inhibition of uptake of transferrin-bound iron by human hepatoma cells by nontransferrin-bound iron. Hepatology. 1997;26:691–698. [PubMed]
  • Wang CY, Jenkitkasemwong S, Duarte S, Sparkman BK, Shawki A, Mackenzie B, Knutson MD. ZIP8 Is an Iron and Zinc Transporter Whose Cell-surface Expression Is Up-regulated by Cellular Iron Loading. J Biol Chem. 2012;287:34032–34043. [PMC free article] [PubMed]
  • Wang CY, Knutson MD. Hepatocyte divalent metal-ion transporter-1 is dispensable for hepatic iron accumulation and non-transferrin-bound iron uptake in mice. Hepatology. 2013;58:788–798. [PMC free article] [PubMed]
  • Zhao N, Gao J, Enns CA, Knutson MD. ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J Biol Chem. 2010;285:32141–32150. [PMC free article] [PubMed]
  • Zhou XY, Tomatsu S, Fleming RE, Parkkila S, Waheed A, Jiang J, Fei Y, Brunt EM, Ruddy DA, Prass CE, Schatzman RC, O’Neill R, Britton RS, Bacon BR, Sly WS. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A. 1998;95:2492–2497. [PubMed]